Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics. CA Cancer J Clin 64:9–29
Article
Google Scholar
Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, Van Poppel H et al (2005) EAU guidelines on prostate cancer. Eur Urol 48:546–551
Article
CAS
Google Scholar
Kosuri S, Akhtar NH, Smith M, Osborne JR, Tagawa ST (2012) Review of salvage therapy for biochemically recurrent prostate cancer: the role of imaging and rationale for systemic salvage targeted anti-prostate specific membrane antigen radioimmunotherapy. Adv Urol 2012:921674
Article
Google Scholar
Bott SRJ (2004) Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 7:211–216
Article
CAS
Google Scholar
Beer AJ, Eiber M, Souvatzoglou M et al (2011) Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 12:181–191
Article
Google Scholar
Oyen RH, Van Poppel HP, Ameye FE et al (1994) Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 190:315–322
Article
CAS
Google Scholar
Liu Y, Zuckier LS, Ghesani NV (2010) Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res 30(2):369–374
PubMed
Google Scholar
Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A (2012) Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem 113(2):553–562
Article
CAS
Google Scholar
Castellucci P, Picchio M (2013) 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 40(suppl 1):S36–S40
Article
Google Scholar
Krause BJ, Souvatzoglou M, Tuncel M et al (2008) The detection rate of [11C] choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35:18–23
Article
CAS
Google Scholar
Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N et al (2009) Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 69:6932–6940
Article
CAS
Google Scholar
Eder M, Schäfer M, Bauder-Wüst U, Hull WE, Wängler C, Mier W et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–697
Article
CAS
Google Scholar
Schäfer M, Bauder-Wüst U, Leotta K, Zoller F, Mier W, Haberkorn U et al (2012) A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res 2:23
Article
Google Scholar
Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3:216–225
Article
CAS
Google Scholar
Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V et al (1997) Monoclonal antibodies to the extracellular domain of prostate specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629–3634
CAS
PubMed
Google Scholar
Sweat SD, Pacelli A, Murphy GP, Bostwick DG (1998) Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52:637–640
Article
CAS
Google Scholar
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 15:167–172
Article
CAS
Google Scholar
Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S et al (2011) 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pen tanedioic acid,[18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res 17:7645–7653
Article
CAS
Google Scholar
Eder M, Eisenhut M, Babich J, Haberkorn U (2013) PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 40:819–823
Article
Google Scholar
Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M et al (2014) Comparison of PET/CT and PET/MRI hybrid systems using a (68)Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging 41:887–897
Article
CAS
Google Scholar
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486–495
Article
CAS
Google Scholar
Afshar-OromiehA ZCM, MalcherA EM, Eisenhut M, Linhart HG et al (2014) Comparison of PET imaging with a (68)Ga -labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41:11–20
Article
Google Scholar
Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B et al (2014) Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 41:1280–1292
Article
CAS
Google Scholar
Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T et al (2009) Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen targeted imaging agent for prostate cancer. J Nucl Med 50:2042–2048
Article
CAS
Google Scholar
Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51:1293–1300
Article
CAS
Google Scholar
Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L (2016) Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl Med Commun 37(11):1169–1179
Article
CAS
Google Scholar
Wallitt KL, Khan SR, Dubash S, Tam HH, Khan S, Barwick TD (2017) Clinical PET Imaging in Prostate Cancer. Radiographics 37:1512–1536
Article
Google Scholar
Krohn T, Verburg FA, Pufe T et al (2015) [68Ga] PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 42(2):210–214
Article
Google Scholar
Beheshti M, Rezaee A, Langsteger W (2017) 68Ga-PSMA-HBED uptake on cervicothoracic (stellate) ganglia, a common pitfall on PET/CT. Clin Nucl Med 42(3):195–196
Article
Google Scholar
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42:197–209
Article
CAS
Google Scholar
Galen RS (1980) Predictive values and efficiency of laboratory testing. Pediat J Clin North Am 27:861–869
Article
CAS
Google Scholar
Roethke MC, Kuru TH, Afshar-Oromieh A, Schlemmer HP, Hadaschik BA, Fenchel M (2013) Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. Eur Urol 64:862–864
Article
Google Scholar
Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K et al (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362
CAS
PubMed
Google Scholar
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3:81–85
CAS
PubMed
Google Scholar
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner F-P, Kübler H, Haberhorn U, Eisenhut M, Hans-JürgenWester, Gschwend JE, Schwaiger M (2015) Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 56:668–674
Article
Google Scholar
Mattiolli AB, Santos A, Vicente A, Queiroz M, Bastos D, Herchenhorn D, Srougi M, Peixoto FA, Morikawa L, da Silva JLF, Etchebehere E (2018) Impact of 68GA-PSMA PET /CT on treatment of patients with recurrent / metastatic high risk prostate cancer – a multicenter study. Int Braz J Urol 44:892–899
Article
Google Scholar
Fitzpatrick L, Lynch O, Marignol L (2017) 68Ga-PSMA-PET/CT has a role in detecting prostate cancer lesions in patients with recurrent disease. Anticancer Res 37:2753–2760
CAS
PubMed
Google Scholar
Aloÿse Fourquet, Cyrielle Aveline, Olivier Cussenot, Gilles Créhange, Françoise Montravers,Jean-Noël Talbot , Mathieu Gauthé (2020) 68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients’ disease management and adequacy of impact 10:2104.